Antiretroviral Therapy Crucial in Preventing non-Hodgkin Lymphoma, YSPH Study Reinforces
A research team led by the Yale School of Public Health has found that for people living with HIV/AIDS, both recent immunosuppression and prolonged HIV viremia play important and independent roles in the development of non-Hodgkin lymphoma.
Study reveals new way to ‘rewire’ immune cells to slow tumor growth
Inside a tumor, immune cells and cancer cells battle for survival. The advantage may go to the cells that metabolize the most glucose, say Yale researchers who have identified a new way to boost immune response by metabolically “rewiring” immune cells.
Targeting a Deadly Type of Uterine Cancer
Endometrial cancer, which originates in the lining of the uterus and is the most common type of gynecological cancer, often has a good prognosis. Patients with the more frequently diagnosed type I are often cured. Type II, however, is responsible for most of the recurrences and deaths that occur in endometrial cancer. Uterine Serous Carcinoma (USC), the most aggressive kind of type II endometrial cancer, accounts for just 10 percent of endometrial tumors and is particularly deadly: in its earliest stages the survival rate can be as low as 50 percent, and for those with more advanced disease, there is no cure.
$7.5 Million Grant to Yale Researchers for Role of Viruses in Cancer
The National Cancer Institute recently awarded a five-year, $7.5 million program project grant to investigators at the Yale School of Medicine to continue studies on the role of viruses and mutant cellular proteins in tumorigenic transformation of cells.
Yale Cancer Center Experts Present New Research at Hematology Annual Meeting
Physicians and scientists from Yale Cancer Center, part of Yale School of Medicine, will present new research at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, Calif., from December 9 to 12.
Yale Researchers Develop New Testing Criteria for Hereditary Stomach Cancer
Yale researchers have shown that individuals who carry a mutation in the CDH1 gene have a 30% to 40% risk of developing stomach cancer during their lifetime. Yet many people with the rare inherited condition remain unaware that they have it.
Yale scientists chosen by White House to expedite cancer research
Yale is one of three institutions that have been honored with the White House Cancer Moonshot research grant. Yale's Douglas Hanlon, PhD, research scientist in dermatology, and Richard Edelson, MD, the Anthony N. Brady Professor of Dermatology, describe their groundbreaking research, using mRNA technology to create a vaccine that targets only cancer cells.Source: WTNH News 8
YSPH alumna Margaret Mayer embraces challenge of grant management at the National Cancer Institute
This Alumni Spotlight focuses on Margaret Mayer, PhD ’19 (Chronic Disease Epidemiology), MPH ’16 (Chronic Disease Epidemiology), the program director in the Tobacco Cancer Research Branch at the National Cancer Institute.
Overdiagnosis and Preventative Screening: A Q&A With Ilana Richman
In a Q&A, Ilana Richman, MD, MHS, assistant professor of medicine (general medicine), discusses why overdiagnosis is a concern, the challenges of assessing the benefit of new screening technologies, and the risks and benefits people should weigh when considering preventative screening.
Sang Taek Kim Returns to YSM to Lead Immunotherapy Adverse Events Program
A physician scientist, Sang Taek Kim, MD, PhD, assistant professor of medicine (rheumatology), is interested in the autoimmune complications induced by cancer immunotherapy. In his new role, he serves as director of the Immunotherapy Adverse Events in Rheumatology Program.